{"id":444,"date":"1997-12-01T12:06:00","date_gmt":"1997-12-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1997\/emetogenes-potential-von-zytostatika"},"modified":"2022-03-17T14:08:36","modified_gmt":"2022-03-17T13:08:36","slug":"emetogenes-potential-von-zytostatika","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1997\/emetogenes-potential-von-zytostatika","title":{"rendered":"Emetogenes Potential von Zytostatika"},"content":{"rendered":"<p>Onkologen aus den USA und Italien haben mit finanzieller Unterst\u00fctzung der Firma Glaxo Wellcome ein neues einfaches Klassifikationsschema vorgeschlagen, das Klinikern die Einsch\u00e4tzung des emetogenen Potentials von Zytostatika erleichtern und dadurch eine individuelle antiemetische Therapie erm\u00f6glichen soll (Hesketh, P.J., et al.: J. Clin. Oncol. 1997, 15, 103). Diese Klassifikation in f\u00fcnf Stufen basiert auf einer [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Onkologen aus den USA und Italien haben mit finanzieller Unterst\u00fctzung der Firma Glaxo Wellcome ein neues einfaches Klassifikationsschema vorgeschlagen, das Klinikern die Einsch\u00e4tzung des emetogenen Potentials von Zytostatika erleichtern und dadurch eine individuelle antiemetische Therapie erm\u00f6glichen soll (Hesketh, P.J., et al.: J. Clin. Oncol. 1997, 15, 103). Diese Klassifikation in f\u00fcnf Stufen basiert auf einer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[189,268,704,33,701,271,705,30,188,27,457,700,274,703,699,706,702,392,393,270,39,35,707,710,276,708,279,280,709,266,698,696,265,697,262,264],"class_list":["post-444","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-2-chlordesoxyadenosin","tag-5-fluorouracil","tag-bleomycin","tag-busulfan","tag-carmustin","tag-chemotherapie","tag-chlorambucil","tag-cisplatin","tag-cladribin","tag-cyclophosphamid","tag-cytarabin","tag-dacarbazin","tag-docetaxel","tag-doxorubicin","tag-emesis","tag-epirubicin","tag-erbrechen","tag-etoposid","tag-fludarabin","tag-gemcitabin","tag-hydroxycarbamid","tag-hydroxyurea","tag-idarubicin","tag-ifosfamid","tag-methotrexat","tag-mitomycin","tag-mitoxantron","tag-paclitaxel","tag-procarbacin","tag-streptozocin","tag-thioguanin","tag-vinblastin","tag-vincristin","tag-vinorelbin","tag-zytostatika","tag-zytostatische-therapie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=444"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/444\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}